title: Malaria prophylaxis in post renal transplant recipients in the tropics: is it necessary?
abstract: OBJECTIVE
  Malaria prophylaxis is usually not provided routinely for most post renal transplant recipients in malaria endemic zones. Therefore, very little information is known about the incidence and severity of this disease among the post-transplant recipients in our environment. Hence a prospective, non-randomized open label clinical trial to determine the incidence of malaria and the beneficial effect of malaria prophylaxis among renal transplant recipients in Nigeria was carried out.
  
  
  METHODS
  All seven consecutive patients who had renal transplants and returned to the unit not more than four weeks later were seen and followed up. This consisted of an initial four week period of no prophylaxis and another four weeks of prophylaxis with proguanil hydrochloride 200 mg daily. Weekly thin and thick blood films by Giemsa stain were examined and other routine investigations of liver function tests, full blood count, urea, creatinine, electrolytes and urinalysis were done.
  
  
  RESULTS
  Only three out of the seven patients (42.8%) had positive smears for malaria parasites in the initial no prophylaxis phase. No malaria parasites were detected at the prophylactic phase. There was no significant difference in the results of other investigations including the renal function between the two phases.
  
  
  CONCLUSIONS
  This study has shown the benefit of short term routine malaria prophylaxis among renal transplant recipients in malaria endemic zones.
authors.affiliation: Nephrology Unit, Department of Medicine, National Hospital, Central District (Phase II), PMB425, Garki-Abuja, Nigeria. anteyiemma@yahoo.com
authors.forename: E A
authors.initials: EA
authors.lastname: Anteyi
authors.forename: H M
authors.initials: HM
authors.lastname: Liman
authors.forename: A
authors.initials: A
authors.lastname: Gbaji
mesh_terms: D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage*; D018890:Chemoprevention; D006784:Hospitals, Teaching; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D016778:Malaria, Falciparum / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000302:isolation & purification; D002727:Proguanil / Q000008:administration & dosage*; D011446:Prospective Studies; D014329:Tropical Climate
chemical_list: D000962:Antimalarials; D002727:Proguanil